Driven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Now, after Novartis’ $9.7 billion agreement to pick up The Medicines Company, the rumor mill
read moreCDMOs are building gene therapy and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and private players is working
read moreThe company intends to file a Marketing Authorisation Application (MAA) in the first half of next year, based on Phase II and III trials. More: FDA ‘yes’ brings SK Biopharma’s seizure drug one step closer to Europe Source: News
read moreThe acquisition was decided on the back of The Medicines Company’s inclisiran trials. More: Novartis set to buy The Medicines Company in .7bn deal Source: News
read moreThe results mark the first time in a decade that a treatment has improved overall survival for the indication. More: Tecentriq, Avastin combo extends liver cancer survival Source: News
read moreCurrently, a significant number of patients deemed “at risk” are implanted with implantable cardioverter-defibrillators that are never needed, which can be severely detrimental to their overall health. More: Creavo initiates sudden cardiac death trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals